Synapse - Works

Results (21)

A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma

Meeting Abstract

Park, J. H.; Palomba, M. L.; Devlin, S. M.; Valtis, Y. K.; Sikder, D. S.; Senechal, B.; Wang, X.; Cathcart, E.; Liotta, K.; Yu, A.; more...
Blood (2023)

Fulltext@MSK | Save

An ongoing pilot study of targeted radioimmunotherapy (131-I apamistamab) conditioning prior to CD19-targeted CAR T-cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma

Meeting Abstract

Geyer, M. B.; Cadzin, B.; Hosszu, K.; Senechal, B.; Spross, J. A.; Mark, A.; Desai, A.; Cathcart, E. R.; Palomba, M. L.; Pandit-Taskar, N.
Blood (2022)

Fulltext@MSK | Save

Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma

Meeting Abstract

Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
Blood (2021)

Fulltext@MSK | Save

Iomab with adoptive cellular therapy (Iomab-ACT): A pilot study of 131-I apamistamab followed by CD19-targeted car T-cell therapy for patients with relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma

Meeting Abstract

Geyer, M. B.; Cadzin, B.; Halton, E.; Kane, P.; Senechal, B.; Geoghegan, E. M.; Reddy, V.; Berger, M. S.; Ludwig, D.; Pandit-Taskar, N.; more...
Blood (2021)

Fulltext@MSK | Save

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Journal Article

Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
Blood (2021)

Fulltext@MSK | Save

Phase 2 trial of single-agent cobimetinib for adults with BRAF V600-mutant and wild-type histiocytic disorders

Meeting Abstract

Diamond, E. L.; Durham, B. H.; Dogan, A.; Hyman, D. M.; Rampal, R. K.; Ulaner, G.; Brody, L.; Abdel-Wahab, O.
Blood (2017)

Fulltext@MSK | Save

High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis

Journal Article

Papo, M.; Diamond, E. L.; Cohen-Aubart, F.; Emile, J. F.; Roos-Weil, D.; Gupta, N.; Durham, B. H.; Ozkaya, N.; Dogan, A.; Ulaner, G. A.; more...
Blood (2017)

Fulltext@MSK | Save

Phase I trial of the targeted alpha-particle nano-generator actinium-225 (ac-225)-lintuzumab (anti-CD33; HuM195) in acute myeloid leukemia (AML)

Meeting Abstract

Jurcic, J. G.; Rosenblat, T. L.; McDevitt, M. R.; Pandit-Taskar, N.; Carrasquillo, J. A.; Chanel, S. M.; Zikaras, K.; Frattini, M. G.; Maslak, P. G.; Cicic, D.; more...
Blood (2011)

Fulltext@MSK | Save

Effects of long term imatinib on bone mineral density in patients with chronic myelogenous leukemia (CML) or gastrointestinal stromal tumor (GIST)

Meeting Abstract

Berman, E.; Maki, R.; Farooki, A.; Girotra, M.; Chanel, S.; Cheng, C.; Strauss, H. W.; Fleisher, M.
Blood (2010)

Fulltext@MSK | Save

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213 ((213)Bi)-labeled-HuM195 (lintuzumab) for acute myeloid leukemia (AML)

Meeting Abstract

Rosenblat, T.; McDevitt, M. R.; Mulford, D. A.; Pandit-Taskar, N.; Weiss, M. A.; Heaney, M. L.; Chanel, S.; Morgenstern, A.; Larson, S. M.; Scheinberg, D. A.; more...
Blood (2008)

Fulltext@MSK | Save